Tab Sitagliptin

# Tab sitagliptin ## Overview - **Classification**: Dipeptidyl peptidase-4 (DPP-4) inhibitor, Antidiabetic agent - **Mechanism**: Inhibits the DPP-4 enzyme, increasing active incretin hormones (GLP-1, GIP). This enhances glucose-dependent insulin release and suppresses glucagon secretion. ## Primary Indications 1. **Type 2 Diabetes Mellitus (T2DM)** - as an adjunct to diet and exercise to improve glycemic control in adults. 2. **Monotherapy or Combination** - Can be used alone or with other antidiabetic agents (e.g., metformin, sulfonylureas, thiazolidinediones, insulin). ## Adult Dosing ### Standard Dosing **Type 2 Diabetes Mellitus** - **Dose**: **100 mg** - **Frequency**: Once daily - **Route**: Oral - **Maximum**: **100 mg** per day ### Dose Adjustments - **Renal Impairment**: - CrCl ≥ 45 mL/min: No dose adjustment needed. - CrCl 30 to < 45 mL/min: **50 mg** once daily. - CrCl < 30 mL/min (including ESRD requiring dialysis): **25 mg** once daily. - Can be taken without regard to dialysis timing. - **Hepatic Impairment**: No dose adjustment for mild to moderate impairment. Not studied in severe impairment. - **Elderly Patients**: No specific dose adjustment based on age alone. Adjust for renal function if impaired. ## Pediatric Dosing ### Neonates (0-28 days) - **Not indicated**. Safety and efficacy have not been established in this age group. - **Special Notes**: Use is not recommended. ### Infants (1-12 months) - **Not indicated**. Safety and efficacy have not been established in this age group. - **Special Notes**: Use is not recommended. ### Children (1-12 years) - **Not indicated**. Safety and efficacy have not been established in this age group. - **Special Notes**: Use is not recommended. ### Adolescents (13-18 years) - **Not indicated**. Safety and efficacy have not been established in this age group. - **Special Notes**: Use is not recommended. ## Safety Information ### Contraindications - **Absolute**: History of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema) to sitagliptin. ### Common Adverse Effects - **Common (1-10%)**: Nasopharyngitis, headache, upper respiratory tract infection. - **Serious but Rare**: Pancreatitis (acute), severe hypersensitivity reactions (anaphylaxis, angioedema, SJS), bullous pemphigoid, severe arthralgia, heart failure. - **Serious but Rare**: Hypoglycemia (when used with insulin or sulfonylurea). ### Key Drug Interactions - **Digoxin**: Sitagliptin may cause a slight increase in digoxin AUC. Monitor digoxin levels, especially at initiation or dose change. - **Sulfonylureas/Insulin**: Increased risk of hypoglycemia. Consider lower doses of sulfonylurea or insulin. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (eGFR or CrCl). - **During Treatment**: - Monitor HbA1c periodically (e.g., every 3-6 months) for glycemic control. - Monitor renal function periodically, especially in patients with impaired function. - Monitor for symptoms of pancreatitis (severe, persistent abdominal pain). - Monitor for signs of hypersensitivity reactions or bullous pemphigoid (skin blistering). - Monitor for severe and disabling arthralgia. - **Clinical Signs**: Watch for unexplained severe abdominal pain, rash/swelling, skin blisters, severe joint pain, or signs of heart failure (e.g., dyspnea, sudden weight gain). ## Clinical Pearls - 💡 **Tip 1**: Sitagliptin can be taken with or without food at any time of day. - 💡 **Tip 2**: If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose. - 💡 **Tip 3**: Counsel patients on the symptoms of pancreatitis, severe joint pain, and hypersensitivity reactions, and to seek medical attention immediately if they occur. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.